National Coverage Determination (NCD 90.2): Next Generation Sequencing (NGS) for Medicare Beneficiaries with Germline (Inherited) Cancer


This article, based on CR 11837, informs you about National Coverage Determination (NCD) 90.2, Next Generation Sequencing (NGS) for Medicare Beneficiaries with germline (inherited) cancer. Effective for dates of service on and after January 27, 2020, the Centers for Medicare & Medicaid Services (CMS) has determined that NGS, as a diagnostic laboratory test, is reasonable and necessary and covered nationally for patients with germline (inherited) cancer when performed in a CLIA-certified laboratory, when ordered by a treating physician, and when specific requirements are met.




Last Updated: 09/16/2020